A redacted sample of a typical HALO™ deliverable for a mid-market PE healthcare services target. All target, sponsor, peer, and quantification detail has been removed for open distribution.
This is a historical five-measure example, not a current four-pillar HALO™ scorecard. Its measure scores and 2.6/5 composite are retained as originally presented and must not be read as Heritage, Audience, Loyalty, or Outlook scores. Current HALO™ averages those four pillars and applies an Integration Drag adjustment where relevant. Target name, sponsor name, peer set, dollar quantifications, primary-research quotations, and source attributions have been removed.
Historical five-measure sample: the scores below have not been recalculated under the current Heritage, Audience, Loyalty, Outlook framework. The current HALO™ score averages those four pillars, adjusted for Integration Drag where applicable.
These historical measures were scored 1 (severe) to 5 (best-in-class). They are supporting evidence under the current framework, not renamed four-pillar scores. The original composite remains a historical result; do not compare it directly with a current HALO™ score.
Historical composite: weighted blend of five legacy measures. Current HALO™ uses the four-pillar average with an Integration Drag adjustment where relevant; this sample has not been rescored.
Primary intelligence with referring physicians, case managers, and payer network leads. Tests prompted and unprompted recall, perceived clinical quality, and likelihood-to-refer against two named regional peers.
| Recall Metric | vs. Peer A | vs. Peer B | vs. Peer C |
|---|---|---|---|
| Unprompted recall, legacy referrer base | [ redacted ] | [ redacted ] | [ redacted ] |
| Unprompted recall, newer referring physicians | [ redacted ] | [ redacted ] | [ redacted ] |
| Perceived clinical-quality rank | [ redacted ] | [ redacted ] | [ redacted ] |
| Likelihood-to-refer (top-2-box) | [ redacted ] | [ redacted ] | [ redacted ] |
| Payer-network lead recall, recent expansion markets | [ redacted ] | [ redacted ] | [ redacted ] |
n = 47 referrer interviews, 12 payer-network interviews · conducted across 4 catchment markets · sample composition methodology in Appendix D.
| Line Item | HALO™ Pillar(s) | Value at Risk |
|---|---|---|
| Organic-discovery revenue exposure (5-year hold) | Pillars 1 & 2 | [ redacted ] |
| Clinician acquisition cost delta (annualized, steady state) | Pillar 4 | [ redacted ] |
| Roll-up brand integration dyssynergy (first 18 months) | Pillar 5 | [ redacted ] |
| Net-new referral capture compression | Pillar 3 | [ redacted ] |
| Total brand-driven enterprise value at risk | Composite | $ [ redacted ] M |
Quantification model assumptions, sensitivity ranges, and reconciliation to commercial DD revenue model in Appendix C. Values are point estimates; full report includes low / base / high cases.
Sequenced post-close interventions to neutralize the brand-driven value at risk identified above. Each item maps to the pillar(s) it addresses and the line item it moves.